What We're Reading: Page 5
Industry reads hand-picked by our editors
Feb 26, 2026
-
CNBC
FDA Commissioner Dr. Makary on rare disease therapy approvals, internal politics at the agency
-
CNN
Takeaways from surgeon general nominee Casey Means’ Senate confirmation hearing
-
STAT
A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
-
The Financial Times
The elusive grail of blood tests that spot cancer early
Feb 25, 2026
-
The Wall Street Journal
Who’s in Charge at the FDA?
-
Axios
Trump touts drug price cuts most Americans may not feel
-
KFF Health News
Hospitals Fighting Measles Confront a Challenge: Few Doctors Have Seen It Before
Feb 24, 2026
Feb 23, 2026
Feb 20, 2026
-
Axios
Big Pharma financially unfazed by White House drug price deals
-
Bloomberg
Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch
-
The Washington Post
After leaving WHO, Trump officials propose more expensive replacement to duplicate it
-
Quanta Magazine
The Biophysical World Inside a Jam-Packed Cell
Feb 19, 2026
Feb 18, 2026
-
Stat
At drugmakers’ forum, Oz gets a friendly embrace, while Makary faces tough questions
-
AP News
Bayer strikes $7.25 billion deal to settle Roundup cancer lawsuits
-
Reuters
Lilly targets India as global export hub amid booming Mounjaro sales, executive says
-
The New York Times
A New Concern About Weight Loss Drugs: What if They Work Too Well?
Previous
